Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction (OBD) - Yahoo Finance

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP - News) today announced the presentation of positive data from a Phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD), at Digestive Disease Week 2012, held ...

Sucampo Presents New Phase III Data from Opioid-Induced Bowel Dysfunction Study - Genetic Engineering News

Sucampo Pharmaceuticals presented new data from a third Phase III trial evaluating lubiprostone in the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic noncancer pain. Initial results from the study were reported in April.

Sucampo Pharmaceuticals, Inc. : Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction (OBD) - 4-traders (press release)

Data Presented in Clinical Practice Distinguished Abstract Plenary Session at Digestive Disease Week 2012 Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the presentation of positive data from a Phase 3 clinical trial of lubiprostone for the ...

Sucampo Presents Data for AMITIZA® in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C) - Yahoo Finance

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP - News) today announced the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA ® (lubiprostone) for the treatment of irritable bowel syndrome with ...

Sucampo (SCMP) Says AMITIZA Had Statistically Significant Results Following Two Phase 3s - StreetInsider.com

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) presents pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA (lubiprostone) for the treatment of irritable bowel syndrome with constipation (IBS-C) at Digestive Disease Week 2012 in San Diego.

Sucampo Pharma: Riding The Waves Of Amitiza - RTT News

Amitiza, whose chemical name is lubiprostone, is an FDA-approved drug for treatment of chronic idiopathic constipation in adults of both genders, and for irritable bowel syndrome with constipation in women aged 18 years and older. Sucampo has been working ...

Sucampo Presents Data for AMITIZA(R) in the Treatment of Moderate to ...  - CNBC

BETHESDA, Md., May 20, 2012 (BUSINESS WIRE) -- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA(R) (lubiprostone) for the treatment of ...

Sucampo Pharmaceuticals, Inc. : Cobiprostone Preclinical Data from NSAID-Induced Gastric Mucosal Injury Models Reported at Digestive Disease Week 2012 - 4-traders (press release)

08:00p Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in O.. 05/20 Sucampo Presents Data for AMITIZA® in the Treatment of Moderate to Very Severe I.. 05/20 Cobiprostone Preclinical Data from NSAID-Induced Gastric Mucosal ...

Drugs in the Pipeline - Monthly Prescribing Reference

Sucampo announced positive data from a Phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD). New Phase 3 study findings show that subcutaneous induction regimens of Simponi (golimumab; Janssen Biotech ...